Hepatitis E vaccine recombinant - Xiamen Innovax

Drug Profile

Hepatitis E vaccine recombinant - Xiamen Innovax

Alternative Names: Hecolin; HEV 239

Latest Information Update: 18 Aug 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Xiamen Innovax Biotech
  • Class Synthetic vaccines; Viral hepatitis vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Hepatitis E

Most Recent Events

  • 01 Jun 2014 Xiamen Innovax initiates enrolment in a phase IV trial for Hepatitis E (Prevention) in China (NCT02189603)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top